Research graph
References from Cooperative Peripheral CB1 Inhibition by Extracellular Antibody Binding and Orthosteric Antagonism. Local targets link to admitted publications; unresolved targets remain external evidence.
10.1126/science.1063545
10.1126/science.1063545 · External reference
10.1124/pr.54.2.161
10.1124/pr.54.2.161 · External reference
10.1038/346561a0
10.1038/346561a0 · External reference
10.1172/jci200317725
10.1172/jci200317725 · External reference
10.1056/nejmoa044537
10.1056/nejmoa044537 · External reference
10.1002/dmrr.764
10.1002/dmrr.764 · External reference
10.3390/biomedicines11020306
10.3390/biomedicines11020306 · External reference
10.1016/0014-5793(94)00773-x
10.1016/0014-5793(94)00773-x · External reference
10.1016/j.lfs.2005.04.017
10.1016/j.lfs.2005.04.017 · External reference
10.1155/2011/432607
10.1155/2011/432607 · External reference
10.1001/jama.295.7.761
10.1001/jama.295.7.761 · External reference
The psychiatric side-effects of rimonabant
10.1590/s1516-44462009000200012 · 2009 · External reference
CB1 antagonists for obesity—what lessons have we learned from rimonabant?
10.1038/nrendo.2009.197 · 2009 · External reference
Peripheral CB1 receptor blockade for treatment of obesity
10.1016/s2213-8587(25)00255-4 · 2025 · External reference
Requiem for rimonabant: therapeutic potential for cannabinoid CB1 receptor antagonists after the fall
10.3390/ddc2030035 · 2023 · External reference
Seventeen years since rimonabant’s downfall: reassessing its suicidality risk profile
10.1002/oby.24019 · 2024 · External reference
The therapeutic potential of targeting the peripheral endocannabinoid/CB1 receptor system
10.1016/j.ejim.2018.01.009 · 2018 · External reference
10.1517/13543784.2012.704019
10.1517/13543784.2012.704019 · External reference
Rehashing endocannabinoid antagonists: can we selectively target the periphery to safely treat obesity and type 2 diabetes?
10.1172/jci44099 · 2010 · External reference
-5006 and JD-5037: peripherally restricted (PR) cannabinoid-1 receptor blockers related to SLV-319 (Ibipinabant) as metabolic disorder therapeutics devoid of CNS liabilities
10.1016/j.bmcl.2012.08.004 · 2012 · External reference
10.1016/j.yrtph.2019.104483
10.1016/j.yrtph.2019.104483 · External reference
10.1053/j.gastro.2012.01.032
10.1053/j.gastro.2012.01.032 · External reference
10.1007/164_2020_404
10.1007/164_2020_404 · External reference
10.1038/nrd.2017.91
10.1038/nrd.2017.91 · External reference
GPCR drug discovery: new agents, targets and indications
10.1038/s41573-025-01139-y · 2025 · External reference
Advances in Therapeutic Antibody Discovery and Development Targeting G Protein-Coupled Receptors
10.1002/prp2.70216 · 2026 · External reference
10.2139/ssrn.6322538
10.2139/ssrn.6322538 · External reference
10.1038/s41467-023-43601-8
10.1038/s41467-023-43601-8 · External reference
10.1016/j.tips.2020.11.013
10.1016/j.tips.2020.11.013 · External reference
Unresolved reference
External reference
-P: Nimacimab, a Peripherally Restricted CB1 Inhibitor, Promotes Metabolic Homeostasis in a Diet-Induced Obesity (DIO) Mouse Model as Demonstrated by Weight Loss, Restored Hormonal Regulation, and Reduced Inflammatory Biomarkers
10.2337/db25-1716-p · 2025 · External reference
Unresolved reference
External reference
Unresolved reference
External reference
Peripherally restricted CB1 receptor blockers
10.1016/j.bmcl.2013.06.066 · 2013 · External reference
10.1074/jbc.ra119.010089
10.1074/jbc.ra119.010089 · External reference
10.1038/nature10954
10.1038/nature10954 · External reference
10.1038/nature14886
10.1038/nature14886 · External reference
Structural insight into apelin receptor-G protein stoichiometry
10.1038/s41594-022-00797-5 · 2022 · External reference
10.1016/s0009-3084(02)00151-2
10.1016/s0009-3084(02)00151-2 · External reference
10.1016/j.lfs.2005.05.011
10.1016/j.lfs.2005.05.011 · External reference
10.1038/s41467-024-50827-7
10.1038/s41467-024-50827-7 · External reference
10.1038/s41467-024-49000-x
10.1038/s41467-024-49000-x · External reference
10.1016/j.cell.2016.10.004
10.1016/j.cell.2016.10.004 · External reference
10.7554/elife.58464
10.7554/elife.58464 · External reference
10.1038/s41421-023-00627-y
10.1038/s41421-023-00627-y · External reference
Non-uniform refinement: adaptive regularization improves single-particle cryo-EM reconstruction
10.1038/s41592-020-00990-8 · 2020 · External reference
cryoSPARC: algorithms for rapid unsupervised cryo-EM structure determination
10.1038/nmeth.4169 · 2017 · External reference
10.1002/pro.3943
10.1002/pro.3943 · External reference
Features and development of Coot
10.1107/s0907444910007493 · 2010 · External reference
ISOLDE: a physically realistic environment for model building into low-resolution electron-density maps
2018 · External reference
Real-space refinement in PHENIX for cryo-EM and crystallography
2018 · External reference
10.1002/jcc.20945
10.1002/jcc.20945 · External reference
Unresolved reference
External reference
10.1002/jcc.24660
10.1002/jcc.24660 · External reference
CHARMM additive all-atom force field for carbohydrate derivatives and its utility in polysaccharide and carbohydrate–protein modeling
10.1021/ct200328p · 2011 · External reference
10.1038/s41467-021-25020-9
10.1038/s41467-021-25020-9 · External reference
Routine microsecond molecular dynamics simulations with AMBER on GPUs. 2. Explicit solvent particle mesh Ewald
10.1021/ct400314y · 2013 · External reference
Long-time-step molecular dynamics through hydrogen mass repartitioning
10.1021/ct5010406 · 2015 · External reference
10.1016/0021-9991(77)90098-5
10.1016/0021-9991(77)90098-5 · External reference
PTRAJ and CPPTRAJ: software for processing and analysis of molecular dynamics trajectory data
10.1021/ct400341p · 2013 · External reference
